Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANS09
- Development stage
- Preclinical
- Lead developer
- Avistone Biotechnology
- Modality
- Small Molecules
01
Overview
ANS09 is an investigational, preclinical-stage drug candidate being developed by Avistone Pharmaceutical for the treatment of solid tumors. As a discovery-stage asset within Avistone's oncology pipeline, the specific biological target and mechanism of action for ANS09 have not yet been publicly disclosed. The compound is part of the company's portfolio of targeted small molecule therapies, which focuses on addressing unmet medical needs in cancer treatment through precision medicine. It is currently undergoing preclinical evaluation to determine its safety and efficacy profile prior to potential clinical advancement.
Beyond the preview
Go deeper on ANS09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANS09.